1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 製品タイプ別スニペット
3.2. 用途別スニペット
3.3. 販売チャネル別スニペット
3.4. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性疾患の増加と高齢化
4.1.1.2. XX
4.1.2. 阻害要因
4.1.2.1. 規制上の課題
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 製品タイプ別
6.1. 製品紹介
6.1.1. 製品タイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（製品タイプ別
6.2. 栄養補助食品
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.2.3. NMN（ニコチンアミドモノヌクレオチド）
6.2.4. PQQ（ピロロキノリンキノン）
6.2.5. アピゲニン
6.2.6. L-トリプトファン
6.2.7. その他
6.3. その他
7. 用途別
7.1. 導入
7.1.1. 市場規模分析および前年比成長率分析（%）, アプリケーション別
7.1.2. 市場魅力度指数：用途別
7.2. 老化抑制*市場
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 心血管疾患
7.4. 癌
7.5. その他
8. 流通チャネル別
8.1. 流通経路
8.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
8.1.2. 市場魅力度指数（流通チャネル別
8.2. 薬局
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. オンライン
8.4. 小売店
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.2.4. 市場規模分析とYoY成長率分析（%）, アプリケーション別
9.2.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.2.6. 市場規模分析および前年比成長率分析（%）, 国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.3.4. 市場規模分析および前年比成長率分析（%）, アプリケーション別
9.3.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.3.6. 市場規模分析および前年比成長率分析（%）, 国別
9.3.6.1. ドイツ
9.3.6.2. イギリス
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.4.4. 市場規模分析および前年比成長率分析 (%)、用途別
9.4.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.4.6. 市場規模分析および前年比成長率分析（%）, 国別
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.5.4. 市場規模分析および前年比成長率分析（%）, アプリケーション別
9.5.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.5.6. 市場規模分析および前年比成長率分析（%）, 国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.6.4. 市場規模分析および前年比成長率分析（%）, アプリケーション別
9.6.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Decode Age*
11.1.1. 会社概要
11.1.2. 製品ポートフォリオと説明
11.1.3. 財務概要
11.1.4. 主な展開
11.2. Zeroharm
11.3. Gataca
11.4. Longevity By Nature
11.5. ProHealth, Inc.
11.6. Xandro Lab.
11.7. NanoSPACE
11.8. AgeX Therapeutics, Inc.
11.9. T.A. SCIENCES
11.10. Elysium Health, Inc.
リストは網羅的ではありません
12. 付録
12.1. 会社概要とサービス
12.2. お問い合わせ

Overview
The global longevity therapeutics market reached US$ 31.67 billion in 2023 and is expected to reach US$ 52.03 billion by 2031 growing with a CAGR of 6.4% during the forecast period 2024-2031.

Longevity therapeutics, also known as longevity medicine or anti-aging medicine, is a rapidly growing field that focuses on helping people live longer, and lead healthier lives. It employs a multifaceted approach that integrates diverse strategies to address the fundamental processes of aging.
The longevity therapeutics approach encompasses targeted drug therapies, gene-based interventions, regenerative medicine techniques, nutritional supplements, and lifestyle modifications, all of which are aimed at mitigating the detrimental effects of aging and promoting healthy longevity. The market includes various therapeutic categories, including pharmacological treatments, gene therapies, cell therapies, and lifestyle changes, all aimed at addressing different facets of the aging process.

Market Dynamics: Drivers
Rising prevalence of chronic diseases and the aging population
The demand for the global longevity therapeutics market is driven by multiple factors. The increasing prevalence of chronic diseases linked to aging, including cardiovascular diseases, neurodegenerative disorders, cancer, and metabolic disorders, is a major factor propelling the growth of the longevity therapeutics market. As the global population continues to age, the occurrence of these age-related conditions rises.
As per WHO data in October 2022, the increase in the number of individuals aged 65 and older, which is expected to double by 2050 to around 1.5 billion, the rising number of aging population and age-related diseases that would propel will the demand for the longevity therapeutics market. The growing awareness among the aging population regarding the significance of preventive healthcare will drive the demand for supplements, medications, and lifestyle changes designed to enhance longevity and avert age-related illnesses.
Moreover, key players in the industry research activities and developing awareness among individuals, are driving longevity therapeutics market growth. For instance, in February 2024, The Potocsnak Longevity Institute at Northwestern University Feinberg School of Medicine launched the Human Longevity Laboratory, an important longitudinal and cross-sectional study aimed at examining the connection between chronological age (the actual number of years a person has lived) and biological age. This research seeks to understand how these two forms of aging relate to one another across various organ systems and aims to validate interventions that could potentially slow down or reverse the aging process.
Also, in Longevity Technology news in September 2024, combination biologics are emerging as a promising strategy for longevity therapy, particularly in age-related diseases. This approach involves using multiple biological agents that target different pathways simultaneously, potentially enhancing therapeutic efficacy and addressing the complex nature of aging.
Similarly, in February 2024, ADvantage Therapeutics announced the appointment of Professor Makoto Kuro-o to its Scientific Advisory Board, recognizing his advanced contributions to aging research, particularly for discovering the Klotho gene associated with longevity and health in aging. This strategic addition aims to enhance the company's focus on developing therapies for neurodegenerative diseases.

Restraints
Factors such as regulatory challenges, ethical considerations, and limited clinical evidence, are expected to hamper the market.

Segment Analysis
The global longevity therapeutics market is segmented based on product type, application, distribution channels, and region.
The dietary supplements segment accounted for approximately 76.3% of the global longevity therapeutics market share
The dietary supplements segment is expected to hold the largest market share over the forecast period. This segment includes a variety of formulations designed to promote health and longevity. This segment primarily features two categories: nutraceuticals and vitamins and minerals, both of which play crucial roles in enhancing overall health and preventing age-related diseases.
Nutraceuticals, natural compounds extracted from food sources, are crucial players in the longevity therapeutics market. These substances offer health advantages beyond basic nutrition, making them increasingly attractive to consumers who want to extend their health span and reduce the risk of age-related illnesses. Resveratrol, nicotinamide mononucleotide (NMN), and coenzyme Q10 (CoQ10) are key examples of these nutraceuticals.
Nicotinamide mononucleotide (NMN) plays a pivotal role in the longevity market as a supplement aimed at enhancing health and mitigating age-related decline. NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a crucial molecule involved in energy metabolism, DNA repair, and various cellular processes. As individuals age, NAD+ levels naturally decline, which can negatively affect cellular function and contribute to the onset of age-related conditions such as neurodegenerative diseases, metabolic disorders, and decreased energy levels.
Moreover, key players in the industry launching innovative products that would drive this segment's growth in the longevity therapeutics market. For instance, Decode Age introduced the MAG7, (Seven Complex Magnesium), and Coenzyme Q10 (Ubiquinol).
Decode Age, a pioneering health and wellness brand in India, has launched "Decode Blood Age," the country's first blood-based biological age test. This innovative approach aims to provide individuals with insights into their true health status by analyzing specific biomarkers derived from blood samples. Unlike chronological age, which simply reflects the number of years a person has lived, biological age reveals the rate at which an individual's body is aging on a cellular level.
Also, Zeropharm introduced clinically validated NMN 250 MG + Berberine Capsules, each containing 250 mg of high-purity NMN and powerful Berberine. These capsules are formulated to enhance NAD+ levels, boost energy, improve focus, support cellular health, promote heart health, and contribute to long-term longevity. For optimal results, take one capsule daily after your morning meal. Experience increased vitality and overall well-being.
Similarly, TeloX is an innovative, plant-derived supplement that combines a potent blend of therapeutic polyphenols naturally extracted from olive leaf, grapevine, and Superoxide Dismutase (SOD). These phytochemical compounds possess powerful antioxidant properties that neutralize harmful free radicals and provide essential nutrients to support mitochondrial function and promote cellular longevity.

Geographical Analysis
North America accounted for approximately 43.6% of the global longevity therapeutics market share
North America region is expected to hold the largest market share over the forecast period owing to the rising geriatric population and age-related diseases that would drive this market growth. Moreover, growing health consciousness, developments in biomedical research, and increased investment in longevity research and technological advancements would increase longevity therapeutics market growth in this region.
In addition, a major number of key players' presence, strategies such as partnerships & collaborations, and

Key Developments would drive longevity therapeutics market growth. For instance, in April 2024, researchers at the Children’s Hospital of Philadelphia (CHOP) and Stanford Medicine identified the FOXO1 protein as a critical factor in enhancing the longevity and effectiveness of CAR-T cells, which are engineered immune cells used in cancer treatment. This discovery is significant because the success of CAR-T cell therapy hinges on the ability of these cells to survive long enough in the body to effectively combat cancer.
Similarly, in California, in June 2024, Alamar Biosciences, a company focused on precision proteomics for early disease detection, announced the launch of the next phase of the Biomarkers of Aging Challenge Series in collaboration with the Biomarkers of Aging Consortium. This initiative aims to tackle one of the most pressing issues in the field of longevity, the need for reliable biomarkers that accurately reflect biological age.

Market Segmentation
By Product Type
• Dietary Supplements
o NMN (Nicotinamide Mononucleotide)
o PQQ (Pyrroloquinoline quinone)
o Apigenin
o L-Tryptophan
o Others
• Others
By Application
• Senescence Inhibition
• Cardiovascular Diseases
• Cancer
• Others
By Distribution Channel
• Pharmacies
• Online
• Retail Stores
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape
The major global players in the longevity therapeutics market include Decode Age, Zeroharm, Gataca, Longevity By Nature, ProHealth, Inc., Xandro Lab., NanoSPACE, AgeX Therapeutics, Inc., T.A. SCIENCES, and Elysium Health, Inc. among others.

Key Developments
 In September 2024, the Estate, introduced a luxury hospitality concept, has emerged from a collaboration between lifestyle company SBE, its visionary founder Sam Nazarian, and renowned entrepreneur Tony Robbins. This innovative venture seamlessly blends high-end accommodations with cutting-edge health and wellness services, catering to the increasing demand for longevity and disease prevention solutions.
 In April 2024, the Longevity India Initiative, spearheaded by the Indian Institute of Science (IISc), embarks on a mission to propel research on aging and promote extended healthy lifespans in India. This far-reaching endeavor tackles the complex challenges of aging through a holistic, multidisciplinary approach that seamlessly blends expertise from the realms of biology, technology, and healthcare.

Why Purchase the Report?
• To visualize the global longevity therapeutics market segmentation based on product type, application, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the longevity therapeutics market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global longevity therapeutics market report would provide approximately 62 tables, 52 figures, and 183 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Chronic Diseases and Aging Population
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Regulatory Challenges
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Dietary Supplements *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. NMN (Nicotinamide Mononucleotide)
6.2.4. PQQ (Pyrroloquinoline quinone)
6.2.5. Apigenin
6.2.6. L-Tryptophan
6.2.7. Others
6.3. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Senescence Inhibition*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiovascular Diseases
7.4. Cancer
7.5. Others
8. By Distribution Channels
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Pharmacies *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Online
8.4. Retail Stores
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Decode Age*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Zeroharm
11.3. Gataca
11.4. Longevity By Nature
11.5. ProHealth, Inc.
11.6. Xandro Lab.
11.7. NanoSPACE
11.8. AgeX Therapeutics, Inc.
11.9. T.A. SCIENCES
11.10. Elysium Health, Inc.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

❖ 世界の長寿治療薬市場に関するよくある質問(FAQ) ❖

・長寿治療薬の世界市場規模は？
→DataM Intelligence社は2023年の長寿治療薬の世界市場規模を316億7000万米ドルと推定しています。

・長寿治療薬の世界市場予測は？
→DataM Intelligence社は2031年の長寿治療薬の世界市場規模を520億3000万米ドルと予測しています。

・長寿治療薬市場の成長率は？
→DataM Intelligence社は長寿治療薬の世界市場が2024年～2031年に年平均6.4%成長すると予測しています。

・世界の長寿治療薬市場における主要企業は？
→DataM Intelligence社は「Decode Age、Zeroharm、Gataca、Longevity By Nature、ProHealth, Inc.、Xandro Lab.、NanoSPACE、AgeX Therapeutics, Inc.、T.A. SCIENCES、Elysium Health, Inc.など ...」をグローバル長寿治療薬市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。